ETF Series Solutions
Range Cancer Therapeutics ETF
$17.69M
Avg Monthly Net Assets
$16.54M
Total Assets
$12K
Total Liabilities
$16.53M
Net Assets
Range Cancer Therapeutics ETF is an Exchange-Traded Fund in ETF Series Solutions
,
based in Wisconsin,
United States of America.
The fund has one share class
and monthly net assets of $17.69M.
On July 30th, 2024 it reported 78 holdings, the largest
being Geron Corp (2.8%), Enliven Therapeutics Inc (2.7%) and Summit Therapeutics Inc (2.5%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| Range Cancer Therapeutics ETF | C000160229 | XNAS | CNCR |
Holdings
From latest NPORT-P, filed July 30th, 2024 for period ending May 31st, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 2seventy bio Inc | Long | Equity-common | US | $246K | 58K | 1.49 |
| Acrivon Therapeutics Inc | Long | Equity-common | US | $350K | 45K | 2.12 |
| Adicet Bio Inc | Long | Equity-common | US | $163K | 112K | 0.98 |
| Agenus Inc | Long | Equity-common | US | $301K | 19K | 1.82 |
| Allogene Therapeutics Inc | Long | Equity-common | US | $128K | 51K | 0.77 |
| Apollomics Inc | Long | Equity-common | US | $113K | 384K | 0.68 |
| Arcellx Inc | Long | Equity-common | US | $172K | 3K | 1.04 |
| Arcus Biosciences Inc | Long | Equity-common | US | $189K | 13K | 1.15 |
| Arvinas Inc | Long | Equity-common | US | $171K | 5K | 1.03 |
| Aura Biosciences Inc | Long | Equity-common | US | $227K | 31K | 1.37 |
| Autolus Therapeutics PLC | Long | Equity-common | GB | $169K | 40K | 1.02 |
| Bicycle Therapeutics PLC | Long | Equity-common | GB | $223K | 10K | 1.35 |
| Biomea Fusion Inc | Long | Equity-common | US | $144K | 14K | 0.87 |
| BioNTech SE | Long | Equity-common | DE | $249K | 2K | 1.51 |
| Blueprint Medicines Corp | Long | Equity-common | US | $277K | 3K | 1.68 |
| Bristol-Myers Squibb Co | Long | Equity-common | US | $180K | 4K | 1.09 |
| Caribou Biosciences Inc | Long | Equity-common | US | $124K | 43K | 0.75 |
| Compass Therapeutics Inc | Long | Equity-common | US | $167K | 119K | 1.01 |
| Cullinan Therapeutics Inc | Long | Equity-common | US | $320K | 14K | 1.93 |
| Day One Biopharmaceuticals Inc | Long | Equity-common | US | $215K | 16K | 1.30 |
| Deciphera Pharmaceuticals Inc | Long | Equity-common | US | $369K | 14K | 2.23 |
| Enliven Therapeutics Inc | Long | Equity-common | US | $450K | 20K | 2.72 |
| Erasca Inc | Long | Equity-common | US | $279K | 111K | 1.69 |
| Exelixis Inc | Long | Equity-common | US | $221K | 10K | 1.34 |
| Exscientia Plc | Long | Equity-common | GB | $183K | 35K | 1.11 |
| Fate Therapeutics Inc | Long | Equity-common | US | $117K | 32K | 0.71 |
| First American Government Obligations Fund | Long | Short-term investment vehicle | US | $28K | 28K | 0.17 |
| Foghorn Therapeutics Inc | Long | Equity-common | US | $222K | 38K | 1.34 |
| Genelux Corp | Long | Equity-common | US | $100K | 37K | 0.61 |
| Genmab A/S | Long | Equity-common | DK | $214K | 8K | 1.30 |
| Geron Corp | Long | Equity-common | US | $467K | 132K | 2.82 |
| Ginkgo Bioworks Holdings Inc | Long | Equity-common | US | $115K | 217K | 0.69 |
| HUTCHMED China Ltd | Long | Equity-common | HK | $254K | 14K | 1.54 |
| Ideaya Biosciences Inc | Long | Equity-common | US | $188K | 5K | 1.14 |
| IGM Biosciences Inc | Long | Equity-common | US | $188K | 23K | 1.14 |
| Immatics NV | Long | Equity-common | DE | $212K | 19K | 1.28 |
| Immuneering Corp | Long | Equity-common | US | $110K | 79K | 0.67 |
| ImmunityBio Inc | Long | Equity-common | US | $301K | 47K | 1.82 |
| Immunocore Holdings PLC | Long | Equity-common | GB | $187K | 4K | 1.13 |
| Innate Pharma SA | Long | Equity-common | FR | $250K | 91K | 1.51 |
| Iovance Biotherapeutics Inc | Long | Equity-common | US | $144K | 16K | 0.87 |
| iTeos Therapeutics Inc | Long | Equity-common | US | $359K | 21K | 2.17 |
| Janux Therapeutics Inc | Long | Equity-common | US | $326K | 6K | 1.97 |
| Karyopharm Therapeutics Inc | Long | Equity-common | US | $166K | 172K | 1.01 |
| Kura Oncology Inc | Long | Equity-common | US | $216K | 10K | 1.31 |
| Kymera Therapeutics Inc | Long | Equity-common | US | $187K | 6K | 1.13 |
| Legend Biotech Corp | Long | Equity-common | US | $139K | 3K | 0.84 |
| Lyell Immunopharma Inc | Long | Equity-common | US | $288K | 104K | 1.74 |
| MacroGenics Inc | Long | Equity-common | US | $59K | 14K | 0.35 |
| Merck & Co Inc | Long | Equity-common | US | $240K | 2K | 1.45 |
| Mersana Therapeutics Inc | Long | Equity-common | US | $107K | 46K | 0.65 |
| Merus NV | Long | Equity-common | NL | $275K | 5K | 1.66 |
| Monte Rosa Therapeutics Inc | Long | Equity-common | US | $156K | 38K | 0.94 |
| MorphoSys AG | Long | Equity-common | DE | $236K | 13K | 1.43 |
| Nurix Therapeutics Inc | Long | Equity-common | US | $258K | 16K | 1.56 |
| Nuvalent Inc | Long | Equity-common | US | $178K | 3K | 1.08 |
| Nuvation Bio Inc | Long | Equity-common | US | $326K | 105K | 1.97 |
| Precigen Inc | Long | Equity-common | US | $225K | 161K | 1.36 |
| Prelude Therapeutics Inc | Long | Equity-common | US | $199K | 52K | 1.20 |
| RAPT Therapeutics Inc | Long | Equity-common | US | $110K | 27K | 0.66 |
| Recursion Pharmaceuticals Inc | Long | Equity-common | US | $177K | 21K | 1.07 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $235K | 240 | 1.42 |
| Relay Therapeutics Inc | Long | Equity-common | US | $181K | 28K | 1.09 |
| Repare Therapeutics Inc | Long | Equity-common | CA | $153K | 44K | 0.93 |
| Replimune Group Inc | Long | Equity-common | US | $137K | 26K | 0.83 |
| REVOLUTION Medicines Inc | Long | Equity-common | US | $276K | 7K | 1.67 |
| Schrodinger Inc/United States | Long | Equity-common | US | $192K | 9K | 1.16 |
| SpringWorks Therapeutics Inc | Long | Equity-common | US | $193K | 5K | 1.17 |
| Summit Therapeutics Inc | Long | Equity-common | US | $421K | 48K | 2.55 |
| Sutro Biopharma Inc | Long | Equity-common | US | $242K | 57K | 1.47 |
| Syndax Pharmaceuticals Inc | Long | Equity-common | US | $196K | 10K | 1.18 |
| Tango Therapeutics Inc | Long | Equity-common | US | $175K | 25K | 1.06 |
| Tyra Biosciences Inc | Long | Equity-common | US | $210K | 13K | 1.27 |
| Vor BioPharma Inc | Long | Equity-common | US | $168K | 125K | 1.02 |
| Xencor Inc | Long | Equity-common | US | $248K | 10K | 1.50 |
| Y-mAbs Therapeutics Inc | Long | Equity-common | US | $186K | 15K | 1.12 |
| Zentalis Pharmaceuticals Inc | Long | Equity-common | US | $194K | 16K | 1.17 |
| Zymeworks Inc | Long | Equity-common | US | $181K | 21K | 1.10 |
Address
ETF Series Solutions
c/o U.S. Bancorp Fund Services LLC
615 East Michigan Street
Milwaukee
Wisconsin
53202
United States of America
Websites
Directors
Leonard M. Rush
David A. Massart
Janet D. Olsen
Michael A. Castino
Transfer Agents
U.S. Bancorp Fund Services, LLC
Pricing Services
ICE Data Pricing & Reference Data, LLC
Custodians
U.S. Bank National Association
Shareholder Servicing Agents
N/A
Admins
U.S. Bancorp Fund Services, LLC
Brokers
VIRTU AMERICAS LLC
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
MISCHLER FINANCIAL GROUP, INC.
BOFAML SECURITIES, INC.
GOLDMAN SACHS & CO. LLC